You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePalbociclib
Accession NumberDB09073
TypeSmall Molecule
GroupsApproved
DescriptionPalbociclib is an oral, reversible, selective, small-molecule inhibitor of CDK4 and CDK6 indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. CDK4 and CDK6 along with their regulatory partner cyclin D1 play a key role in regulating the G1- to S-phase cell-cycle transition via regulation of phosphorylation of the retinoblastoma (Rb) protein. Inhibition of these proteins leads to reduced phosphorylation of Rb, inhibition of downstream signalling, and increased tumor growth arrest. Palbociclib received an accelerated approval from the Food and Drug Administration on February 3, 2015.
Structure
Thumb
Synonyms
6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one
External Identifiers
  • PD 0332991
  • PD 332991
  • PD-0332991
  • PD-332991
  • PD0332991
  • PD332991
  • UNII-G9ZF61LE7G
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
IbranceCapsule75 mg/1OralPfizer Laboratories Div Pfizer Inc2015-02-03Not applicableUs
IbranceCapsule75 mgOralPfizer Canada Inc2016-04-20Not applicableCanada
IbranceCapsule100 mg/1OralPfizer Laboratories Div Pfizer Inc2015-02-03Not applicableUs
IbranceCapsule100 mgOralPfizer Canada Inc2016-04-19Not applicableCanada
IbranceCapsule125 mg/1OralPfizer Laboratories Div Pfizer Inc2015-02-03Not applicableUs
IbranceCapsule125 mgOralPfizer Canada Inc2016-04-19Not applicableCanada
IbranceCapsule125 mg/1OralU.S. Pharmaceuticals2015-02-03Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Palbociclib Isethionate
ThumbNot applicableDBSALT001110
Categories
UNIIG9ZF61LE7G
CAS number571190-30-2
WeightAverage: 447.5328
Monoisotopic: 447.238273207
Chemical FormulaC24H29N7O2
InChI KeyAHJRHEGDXFFMBM-UHFFFAOYSA-N
InChI
InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)
IUPAC Name
6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H,8H-pyrido[2,3-d]pyrimidin-7-one
SMILES
CC(=O)C1=C(C)C2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N(C2CCCC2)C1=O
Pharmacology
IndicationPalbociclib is indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. This indication is approved under accelerated approval based on progression-free survival (PFS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Structured Indications
PharmacodynamicsTreatment of breast cancer cell lines with the combination of palbociclib and antiestrogens leads to decreased retinoblastoma protein (Rb) phosphorylation resulting in reduced E2F expression and signaling and increased growth arrest compared to treatment with each drug alone. In vitro treatment of ER-positive breast cancer cell lines with the combination of palbociclib and antiestrogens leads to increased cell senescence, which was sustained for up to 6 days following drug removal. In vivo studies using a patient-derived ER-positive breast cancer xenograft model demonstrated that the combination of palbociclib and letrozole increased the inhibition of Rb phosphorylation, downstream signaling and tumor growth compared to each drug alone.
Mechanism of actionPalbociclib is an oral, reversible, selective, small-molecule inhibitor of CDK4 and CDK6. CDK4 and CDK6 along with their regulatory partner cyclin D1 play a key role in regulating the G1- to S-phase cell-cycle transition via regulation of phosphorylation of the retinoblastoma (Rb) protein.
TargetKindPharmacological actionActionsOrganismUniProt ID
Cyclin-dependent kinase 4Proteinyes
Inhibitor
HumanP11802 details
Cyclin-dependent kinase 6Proteinyes
Inhibitor
HumanQ00534 details
Related Articles
AbsorptionThe mean Cmax of palbociclib is generally observed between 6 to 12 hours (time to reach maximum concentration, Tmax) following oral administration. The mean absolute bioavailability after an oral 125 mg dose is 46%.
Volume of distribution

The mean apparent distribution of palbociclib is 2583 L, suggesting that palbociclib penetrates extensively into peripheral tissues.

Protein bindingBinding of palbociclib to human plasma proteins in vitro is approximately 85%.
Metabolism

The primary metabolic pathways for palbociclib involve oxidation and sulfonation, with acylation and glucuronidation contributing as minor pathways. Palbociclib is the major circulating drug-derived entity in plasma (23%). The major circulating metabolite was found to be a glucuronide conjugate of palbociclib, although it only represented 1.5% of the administered dose in the excreta.

Route of eliminationPalbociclib was extensively metabolized with unchanged drug accounting for 2.3% and 6.9% of radioactivity in feces and urine, respectively. In feces, the sulfamic acid conjugate of palbociclib was the major drug-related component, accounting for 26% of the administered dose.
Half lifeThe mean plasma elimination half-life is 29 hours.
Clearance

63.1 L/hr

ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbirateroneThe serum concentration of Abiraterone can be increased when it is combined with Palbociclib.Approved
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Palbociclib.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Palbociclib.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Palbociclib.Approved
AdinazolamThe serum concentration of Adinazolam can be increased when it is combined with Palbociclib.Approved
AlbendazoleThe serum concentration of Albendazole can be increased when it is combined with Palbociclib.Approved, Vet Approved
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Palbociclib.Approved
AlfentanilThe serum concentration of Alfentanil can be increased when it is combined with Palbociclib.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Palbociclib.Approved, Investigational
AliskirenThe serum concentration of Aliskiren can be increased when it is combined with Palbociclib.Approved, Investigational
AllylestrenolThe serum concentration of Allylestrenol can be increased when it is combined with Palbociclib.Approved
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Palbociclib.Approved, Investigational
AlogliptinThe serum concentration of Alogliptin can be increased when it is combined with Palbociclib.Approved
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Palbociclib.Approved, Withdrawn
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Palbociclib.Approved, Illicit, Investigational
ALT-110The risk or severity of adverse effects can be increased when Palbociclib is combined with ALT-110.Investigational
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Palbociclib.Approved, Investigational
AmbroxolThe serum concentration of Ambroxol can be increased when it is combined with Palbociclib.Approved
AminophenazoneThe serum concentration of Aminophenazone can be increased when it is combined with Palbociclib.Approved, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Palbociclib.Approved
AmiodaroneThe serum concentration of Palbociclib can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Palbociclib.Approved
AmlodipineThe serum concentration of Amlodipine can be increased when it is combined with Palbociclib.Approved
AmprenavirThe serum concentration of Amprenavir can be increased when it is combined with Palbociclib.Approved
AntipyrineThe serum concentration of Antipyrine can be increased when it is combined with Palbociclib.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Palbociclib.Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Palbociclib.Approved
ApremilastThe serum concentration of Apremilast can be increased when it is combined with Palbociclib.Approved, Investigational
AprepitantThe serum concentration of Aprepitant can be increased when it is combined with Palbociclib.Approved, Investigational
ArgatrobanThe serum concentration of Argatroban can be increased when it is combined with Palbociclib.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Palbociclib.Approved, Investigational
ArtemetherThe serum concentration of Artemether can be increased when it is combined with Palbociclib.Approved
AsenapineThe serum concentration of Asenapine can be increased when it is combined with Palbociclib.Approved
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Palbociclib.Approved, Withdrawn
AtazanavirThe serum concentration of Palbociclib can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Palbociclib can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Palbociclib.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Palbociclib.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Palbociclib.Approved, Investigational
AzelastineThe serum concentration of Azelastine can be increased when it is combined with Palbociclib.Approved
AzithromycinThe serum concentration of Azithromycin can be increased when it is combined with Palbociclib.Approved
BanoxantroneThe serum concentration of Banoxantrone can be increased when it is combined with Palbociclib.Investigational
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Palbociclib.Investigational
BedaquilineThe serum concentration of Bedaquiline can be increased when it is combined with Palbociclib.Approved
BenzphetamineThe serum concentration of Benzphetamine can be increased when it is combined with Palbociclib.Approved, Illicit
Benzyl alcoholThe serum concentration of Benzyl alcohol can be increased when it is combined with Palbociclib.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Palbociclib.Approved, Investigational
BexaroteneThe serum concentration of Palbociclib can be decreased when it is combined with Bexarotene.Approved, Investigational
BezafibrateThe serum concentration of Bezafibrate can be increased when it is combined with Palbociclib.Approved
BicalutamideThe serum concentration of Bicalutamide can be increased when it is combined with Palbociclib.Approved
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Palbociclib.Approved
BoceprevirThe serum concentration of Palbociclib can be increased when it is combined with Boceprevir.Approved
BortezomibThe serum concentration of Bortezomib can be increased when it is combined with Palbociclib.Approved, Investigational
BosentanThe serum concentration of Palbociclib can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Palbociclib.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Palbociclib.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Palbociclib.Approved
BrinzolamideThe serum concentration of Brinzolamide can be increased when it is combined with Palbociclib.Approved
BromazepamThe serum concentration of Bromazepam can be increased when it is combined with Palbociclib.Approved, Illicit
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Palbociclib.Approved, Investigational
BrompheniramineThe serum concentration of Brompheniramine can be increased when it is combined with Palbociclib.Approved
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Palbociclib.Approved
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Palbociclib.Approved, Investigational
BuprenorphineThe serum concentration of Buprenorphine can be increased when it is combined with Palbociclib.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Bupropion can be increased when it is combined with Palbociclib.Approved
BuspironeThe serum concentration of Buspirone can be increased when it is combined with Palbociclib.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Palbociclib.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Palbociclib.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Palbociclib.Approved
CabozantinibThe serum concentration of Cabozantinib can be increased when it is combined with Palbociclib.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Palbociclib.Approved
CalcitriolThe serum concentration of Calcitriol can be increased when it is combined with Palbociclib.Approved, Nutraceutical
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Palbociclib.Approved
CarbamazepineThe serum concentration of Palbociclib can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe serum concentration of Carbinoxamine can be increased when it is combined with Palbociclib.Approved
CariprazineThe serum concentration of Cariprazine can be increased when it is combined with Palbociclib.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Palbociclib.Approved, Investigational
CDX-110The risk or severity of adverse effects can be increased when Palbociclib is combined with CDX-110.Investigational
CelecoxibThe serum concentration of Celecoxib can be increased when it is combined with Palbociclib.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Palbociclib.Approved, Investigational
CephalexinThe serum concentration of Cephalexin can be increased when it is combined with Palbociclib.Approved, Vet Approved
CeritinibThe serum concentration of Palbociclib can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Palbociclib.Withdrawn
CevimelineThe serum concentration of Cevimeline can be increased when it is combined with Palbociclib.Approved
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be increased when it is combined with Palbociclib.Approved
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be increased when it is combined with Palbociclib.Approved, Illicit
ChloroquineThe serum concentration of Chloroquine can be increased when it is combined with Palbociclib.Approved, Vet Approved
ChlorphenamineThe serum concentration of Chlorphenamine can be increased when it is combined with Palbociclib.Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Palbociclib.Approved, Vet Approved
ChlorzoxazoneThe serum concentration of Chlorzoxazone can be increased when it is combined with Palbociclib.Approved
CholecalciferolThe serum concentration of Cholecalciferol can be increased when it is combined with Palbociclib.Approved, Nutraceutical
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Palbociclib.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Palbociclib.Approved
CinacalcetThe serum concentration of Cinacalcet can be increased when it is combined with Palbociclib.Approved
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Palbociclib.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Palbociclib.Approved
ClarithromycinThe serum concentration of Palbociclib can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Palbociclib can be decreased when combined with Clemastine.Approved
ClindamycinThe serum concentration of Clindamycin can be increased when it is combined with Palbociclib.Approved, Vet Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Palbociclib.Approved, Illicit
ClofazimineThe serum concentration of Clofazimine can be increased when it is combined with Palbociclib.Approved, Investigational
ClofibrateThe serum concentration of Clofibrate can be increased when it is combined with Palbociclib.Approved
clomethiazoleThe serum concentration of clomethiazole can be increased when it is combined with Palbociclib.Investigational
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Palbociclib.Approved, Vet Approved
ClonazepamThe serum concentration of Clonazepam can be increased when it is combined with Palbociclib.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Palbociclib.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Palbociclib.Approved, Nutraceutical
ClorazepateThe serum concentration of Clorazepate can be increased when it is combined with Palbociclib.Approved, Illicit
ClotiazepamThe serum concentration of Clotiazepam can be increased when it is combined with Palbociclib.Approved, Illicit
ClotrimazoleThe metabolism of Palbociclib can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Palbociclib is combined with Clozapine.Approved
CobicistatThe serum concentration of Palbociclib can be increased when it is combined with Cobicistat.Approved
CocaineThe serum concentration of Cocaine can be increased when it is combined with Palbociclib.Approved, Illicit
CodeineThe serum concentration of Codeine can be increased when it is combined with Palbociclib.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Palbociclib.Approved
ConivaptanThe serum concentration of Palbociclib can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Palbociclib.Approved
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Palbociclib.Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Palbociclib.Approved
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Palbociclib.Approved
CyclophosphamideThe serum concentration of Cyclophosphamide can be increased when it is combined with Palbociclib.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Palbociclib.Approved, Investigational, Vet Approved
CytarabineThe serum concentration of Cytarabine can be increased when it is combined with Palbociclib.Approved, Investigational
DabrafenibThe serum concentration of Palbociclib can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Daclatasvir can be increased when it is combined with Palbociclib.Approved
DantroleneThe serum concentration of Dantrolene can be increased when it is combined with Palbociclib.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Palbociclib.Approved
DapsoneThe serum concentration of Dapsone can be increased when it is combined with Palbociclib.Approved, Investigational
DarifenacinThe serum concentration of Darifenacin can be increased when it is combined with Palbociclib.Approved, Investigational
DarunavirThe serum concentration of Palbociclib can be increased when it is combined with Darunavir.Approved
DasabuvirThe serum concentration of Dasabuvir can be increased when it is combined with Palbociclib.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Palbociclib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Palbociclib.Approved
DeferasiroxThe serum concentration of Palbociclib can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be increased when it is combined with Palbociclib.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Palbociclib.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Palbociclib.Approved
DesvenlafaxineThe serum concentration of Desvenlafaxine can be increased when it is combined with Palbociclib.Approved
DexamethasoneThe serum concentration of Palbociclib can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextromethorphanThe serum concentration of Dextromethorphan can be increased when it is combined with Palbociclib.Approved
DextropropoxypheneThe serum concentration of Dextropropoxyphene can be increased when it is combined with Palbociclib.Approved, Illicit, Withdrawn
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Palbociclib.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Diclofenac can be increased when it is combined with Palbociclib.Approved, Vet Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Palbociclib.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Palbociclib.Approved
DihydrocodeineThe serum concentration of Dihydrocodeine can be increased when it is combined with Palbociclib.Approved, Illicit
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Palbociclib.Approved
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Palbociclib.Approved
DisopyramideThe serum concentration of Disopyramide can be increased when it is combined with Palbociclib.Approved
DisulfiramThe serum concentration of Disulfiram can be increased when it is combined with Palbociclib.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Palbociclib.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Palbociclib.Approved
DolasetronThe serum concentration of Dolasetron can be increased when it is combined with Palbociclib.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Palbociclib.Approved, Investigational, Vet Approved
DonepezilThe serum concentration of Donepezil can be increased when it is combined with Palbociclib.Approved
DorzolamideThe serum concentration of Dorzolamide can be increased when it is combined with Palbociclib.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Palbociclib.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Palbociclib.Approved, Investigational
DoxycyclineThe metabolism of Palbociclib can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Palbociclib.Approved, Illicit
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Palbociclib.Approved
DutasterideThe serum concentration of Dutasteride can be increased when it is combined with Palbociclib.Approved, Investigational
EfavirenzThe serum concentration of Palbociclib can be decreased when it is combined with Efavirenz.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Palbociclib.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Palbociclib.Approved
ElvitegravirThe serum concentration of Elvitegravir can be increased when it is combined with Palbociclib.Approved
EnalaprilThe serum concentration of Enalapril can be increased when it is combined with Palbociclib.Approved, Vet Approved
EnzalutamideThe serum concentration of Palbociclib can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Palbociclib.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Palbociclib.Approved
ErgocalciferolThe serum concentration of Ergocalciferol can be increased when it is combined with Palbociclib.Approved, Nutraceutical
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Palbociclib.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Palbociclib.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Palbociclib.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Palbociclib.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Palbociclib.Approved, Vet Approved
EscitalopramThe serum concentration of Escitalopram can be increased when it is combined with Palbociclib.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Palbociclib can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe serum concentration of Esomeprazole can be increased when it is combined with Palbociclib.Approved, Investigational
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Palbociclib.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Palbociclib.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe serum concentration of Estradiol valerate/Dienogest can be increased when it is combined with Palbociclib.Approved
EstramustineThe serum concentration of Estramustine can be increased when it is combined with Palbociclib.Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Palbociclib.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be increased when it is combined with Palbociclib.Approved
EszopicloneThe serum concentration of Eszopiclone can be increased when it is combined with Palbociclib.Approved
EthanolThe serum concentration of Ethanol can be increased when it is combined with Palbociclib.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Palbociclib.Approved
EthosuximideThe serum concentration of Ethosuximide can be increased when it is combined with Palbociclib.Approved
EthylmorphineThe serum concentration of Ethylmorphine can be increased when it is combined with Palbociclib.Approved, Illicit
EtonogestrelThe serum concentration of Etonogestrel can be increased when it is combined with Palbociclib.Approved, Investigational
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Palbociclib.Approved
EtoricoxibThe serum concentration of Etoricoxib can be increased when it is combined with Palbociclib.Approved, Investigational
EtravirineThe serum concentration of Palbociclib can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Palbociclib.Approved
ExemestaneThe serum concentration of Exemestane can be increased when it is combined with Palbociclib.Approved, Investigational
FamciclovirThe serum concentration of Famciclovir can be increased when it is combined with Palbociclib.Approved
FelbamateThe serum concentration of Felbamate can be increased when it is combined with Palbociclib.Approved
FelodipineThe serum concentration of Felodipine can be increased when it is combined with Palbociclib.Approved, Investigational
FenofibrateThe serum concentration of Fenofibrate can be increased when it is combined with Palbociclib.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Palbociclib.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Palbociclib.Approved
FinasterideThe serum concentration of Finasteride can be increased when it is combined with Palbociclib.Approved
FingolimodPalbociclib may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Palbociclib.Approved
FluconazoleThe metabolism of Palbociclib can be decreased when combined with Fluconazole.Approved
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Palbociclib.Approved, Investigational
FlunitrazepamThe serum concentration of Flunitrazepam can be increased when it is combined with Palbociclib.Approved, Illicit
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Palbociclib.Approved
FluoxetineThe serum concentration of Fluoxetine can be increased when it is combined with Palbociclib.Approved, Vet Approved
FlurazepamThe serum concentration of Flurazepam can be increased when it is combined with Palbociclib.Approved, Illicit
FlutamideThe serum concentration of Flutamide can be increased when it is combined with Palbociclib.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Palbociclib.Approved
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be increased when it is combined with Palbociclib.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Palbociclib.Approved
FluvoxamineThe metabolism of Palbociclib can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Fosamprenavir can be increased when it is combined with Palbociclib.Approved
FosaprepitantThe serum concentration of Palbociclib can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Palbociclib can be decreased when it is combined with Fosphenytoin.Approved
FulvestrantThe serum concentration of Fulvestrant can be increased when it is combined with Palbociclib.Approved, Investigational
Fusidic AcidThe serum concentration of Palbociclib can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Palbociclib is combined with G17DT.Investigational
GalantamineThe serum concentration of Galantamine can be increased when it is combined with Palbociclib.Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Palbociclib.Approved, Investigational
GemfibrozilThe serum concentration of Gemfibrozil can be increased when it is combined with Palbociclib.Approved
GI-5005The risk or severity of adverse effects can be increased when Palbociclib is combined with GI-5005.Investigational
GlipizideThe serum concentration of Glipizide can be increased when it is combined with Palbociclib.Approved
GlyburideThe serum concentration of Glyburide can be increased when it is combined with Palbociclib.Approved
GranisetronThe serum concentration of Granisetron can be increased when it is combined with Palbociclib.Approved, Investigational
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Palbociclib.Withdrawn
GuanfacineThe serum concentration of Guanfacine can be increased when it is combined with Palbociclib.Approved, Investigational
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Palbociclib.Approved
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Palbociclib.Approved
HalothaneThe serum concentration of Halothane can be increased when it is combined with Palbociclib.Approved, Vet Approved
HexobarbitalThe serum concentration of Hexobarbital can be increased when it is combined with Palbociclib.Approved
Histamine PhosphateThe serum concentration of Histamine Phosphate can be increased when it is combined with Palbociclib.Approved
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Palbociclib.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Palbociclib.Approved, Vet Approved
HydromorphoneThe serum concentration of Hydromorphone can be increased when it is combined with Palbociclib.Approved, Illicit
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be increased when it is combined with Palbociclib.Approved
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Palbociclib.Approved
IdelalisibThe serum concentration of Palbociclib can be increased when it is combined with Idelalisib.Approved
IfosfamideThe serum concentration of Ifosfamide can be increased when it is combined with Palbociclib.Approved
IloperidoneThe serum concentration of Iloperidone can be increased when it is combined with Palbociclib.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Palbociclib.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Palbociclib.Approved
ImiquimodThe serum concentration of Imiquimod can be increased when it is combined with Palbociclib.Approved, Investigational
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Palbociclib.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Palbociclib.Approved
IndinavirThe serum concentration of Palbociclib can be increased when it is combined with Indinavir.Approved
INGN 201The risk or severity of adverse effects can be increased when Palbociclib is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Palbociclib is combined with INGN 225.Investigational
Ipratropium bromideThe serum concentration of Ipratropium bromide can be increased when it is combined with Palbociclib.Approved
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Palbociclib.Approved, Investigational
IsavuconazoniumThe serum concentration of Isavuconazonium can be increased when it is combined with Palbociclib.Approved, Investigational
Isosorbide DinitrateThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Palbociclib.Approved
Isosorbide MononitrateThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Palbociclib.Approved
IsradipineThe serum concentration of Isradipine can be increased when it is combined with Palbociclib.Approved
ItraconazoleThe serum concentration of Palbociclib can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Palbociclib.Approved
IvacaftorThe serum concentration of Palbociclib can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Palbociclib.Approved, Vet Approved
IxabepiloneThe serum concentration of Ixabepilone can be increased when it is combined with Palbociclib.Approved, Investigational
IxazomibThe serum concentration of Ixazomib can be increased when it is combined with Palbociclib.Approved
KetamineThe serum concentration of Ketamine can be increased when it is combined with Palbociclib.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Palbociclib.Approved
KetobemidoneThe serum concentration of Ketobemidone can be increased when it is combined with Palbociclib.Approved
KetoconazoleThe serum concentration of Palbociclib can be increased when it is combined with Ketoconazole.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Palbociclib.Approved, Investigational
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Palbociclib.Approved, Investigational
LaquinimodThe serum concentration of Laquinimod can be increased when it is combined with Palbociclib.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Palbociclib is combined with Leflunomide.Approved, Investigational
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Palbociclib.Approved
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Palbociclib.Approved, Investigational
LetrozoleThe serum concentration of Letrozole can be increased when it is combined with Palbociclib.Approved, Investigational
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Palbociclib.Approved
LevocetirizineThe serum concentration of Levocetirizine can be increased when it is combined with Palbociclib.Approved
Levomethadyl AcetateThe serum concentration of Levomethadyl Acetate can be increased when it is combined with Palbociclib.Approved
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Palbociclib.Approved
LevonorgestrelThe serum concentration of Levonorgestrel can be increased when it is combined with Palbociclib.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be increased when it is combined with Palbociclib.Approved
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Palbociclib.Approved, Vet Approved
LisurideThe serum concentration of Lisuride can be increased when it is combined with Palbociclib.Approved
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Palbociclib.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Palbociclib.Approved
LopinavirThe serum concentration of Palbociclib can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Loratadine can be increased when it is combined with Palbociclib.Approved
LorcaserinThe serum concentration of Lorcaserin can be increased when it is combined with Palbociclib.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Palbociclib.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Palbociclib.Approved, Investigational
LuliconazoleThe serum concentration of Palbociclib can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Palbociclib can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Lumefantrine can be increased when it is combined with Palbociclib.Approved
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Palbociclib.Approved
MacitentanThe serum concentration of Macitentan can be increased when it is combined with Palbociclib.Approved
MaravirocThe serum concentration of Maraviroc can be increased when it is combined with Palbociclib.Approved, Investigational
MebendazoleThe serum concentration of Mebendazole can be increased when it is combined with Palbociclib.Approved, Vet Approved
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Palbociclib.Approved, Investigational
MefloquineThe serum concentration of Mefloquine can be increased when it is combined with Palbociclib.Approved
MeloxicamThe serum concentration of Meloxicam can be increased when it is combined with Palbociclib.Approved, Vet Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Palbociclib.Withdrawn
MethadoneThe serum concentration of Methadone can be increased when it is combined with Palbociclib.Approved
MethaqualoneThe serum concentration of Methaqualone can be increased when it is combined with Palbociclib.Illicit, Withdrawn
MethoxsalenThe serum concentration of Methoxsalen can be increased when it is combined with Palbociclib.Approved
MethoxyfluraneThe serum concentration of Methoxyflurane can be increased when it is combined with Palbociclib.Approved, Vet Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Palbociclib.Approved, Vet Approved
MethyltestosteroneThe serum concentration of Methyltestosterone can be increased when it is combined with Palbociclib.Approved
MetronidazoleThe serum concentration of Metronidazole can be increased when it is combined with Palbociclib.Approved
MexiletineThe serum concentration of Mexiletine can be increased when it is combined with Palbociclib.Approved
MianserinThe serum concentration of Mianserin can be increased when it is combined with Palbociclib.Approved
MibefradilThe serum concentration of Mibefradil can be increased when it is combined with Palbociclib.Withdrawn
MiconazoleThe serum concentration of Miconazole can be increased when it is combined with Palbociclib.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Palbociclib.Approved, Illicit
MifepristoneThe serum concentration of Palbociclib can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Palbociclib.Approved
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Palbociclib.Approved
MitotaneThe serum concentration of Palbociclib can be decreased when it is combined with Mitotane.Approved
ModafinilThe serum concentration of Palbociclib can be decreased when it is combined with Modafinil.Approved, Investigational
MontelukastThe serum concentration of Montelukast can be increased when it is combined with Palbociclib.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Palbociclib.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Palbociclib.Approved, Investigational
NafcillinThe serum concentration of Palbociclib can be decreased when it is combined with Nafcillin.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Palbociclib.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Palbociclib.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Palbociclib is combined with Natalizumab.Approved, Investigational
NateglinideThe serum concentration of Nateglinide can be increased when it is combined with Palbociclib.Approved, Investigational
NefazodoneThe serum concentration of Palbociclib can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Palbociclib can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Palbociclib can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Palbociclib can be decreased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Palbociclib.Approved
NicotineThe serum concentration of Nicotine can be increased when it is combined with Palbociclib.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Palbociclib.Approved
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Palbociclib.Approved, Investigational
NilvadipineThe serum concentration of Nilvadipine can be increased when it is combined with Palbociclib.Approved
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Palbociclib.Approved
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Palbociclib.Approved
NitrazepamThe serum concentration of Nitrazepam can be increased when it is combined with Palbociclib.Approved
NitrendipineThe serum concentration of Nitrendipine can be increased when it is combined with Palbociclib.Approved
NorethisteroneThe serum concentration of Norethisterone can be increased when it is combined with Palbociclib.Approved
NorgestrelThe serum concentration of Norgestrel can be increased when it is combined with Palbociclib.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Palbociclib.Approved
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Palbociclib.Approved
OlopatadineThe serum concentration of Olopatadine can be increased when it is combined with Palbociclib.Approved
OmeprazoleThe serum concentration of Omeprazole can be increased when it is combined with Palbociclib.Approved, Investigational, Vet Approved
OndansetronThe serum concentration of Ondansetron can be increased when it is combined with Palbociclib.Approved
OrphenadrineThe serum concentration of Orphenadrine can be increased when it is combined with Palbociclib.Approved
OsimertinibThe serum concentration of Palbociclib can be increased when it is combined with Osimertinib.Approved
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Palbociclib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Palbociclib.Approved
OxazepamThe serum concentration of Oxazepam can be increased when it is combined with Palbociclib.Approved
OxybutyninThe serum concentration of Oxybutynin can be increased when it is combined with Palbociclib.Approved, Investigational
OxycodoneThe serum concentration of Oxycodone can be increased when it is combined with Palbociclib.Approved, Illicit, Investigational
OxymorphoneThe serum concentration of Oxymorphone can be increased when it is combined with Palbociclib.Approved, Investigational, Vet Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Palbociclib.Approved, Vet Approved
PalonosetronThe serum concentration of Palonosetron can be increased when it is combined with Palbociclib.Approved, Investigational
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Palbociclib.Approved, Investigational
PantoprazoleThe serum concentration of Pantoprazole can be increased when it is combined with Palbociclib.Approved
ParamethadioneThe serum concentration of Paramethadione can be increased when it is combined with Palbociclib.Approved
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Palbociclib.Approved
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Palbociclib.Approved
ParicalcitolThe serum concentration of Paricalcitol can be increased when it is combined with Palbociclib.Approved, Investigational
ParitaprevirThe serum concentration of Paritaprevir can be increased when it is combined with Palbociclib.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Palbociclib.Approved
PentamidineThe serum concentration of Pentamidine can be increased when it is combined with Palbociclib.Approved
PentobarbitalThe serum concentration of Palbociclib can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerampanelThe serum concentration of Perampanel can be increased when it is combined with Palbociclib.Approved
PergolideThe serum concentration of Pergolide can be increased when it is combined with Palbociclib.Approved, Vet Approved, Withdrawn
PerhexilineThe serum concentration of Perhexiline can be increased when it is combined with Palbociclib.Approved
PermethrinThe serum concentration of Permethrin can be increased when it is combined with Palbociclib.Approved, Investigational
PerphenazineThe serum concentration of Perphenazine can be increased when it is combined with Palbociclib.Approved
PethidineThe serum concentration of Pethidine can be increased when it is combined with Palbociclib.Approved
PhenacetinThe serum concentration of Phenacetin can be increased when it is combined with Palbociclib.Withdrawn
PhenobarbitalThe serum concentration of Palbociclib can be decreased when it is combined with Phenobarbital.Approved
PhenoxybenzamineThe serum concentration of Phenoxybenzamine can be increased when it is combined with Palbociclib.Approved
PhenprocoumonThe serum concentration of Phenprocoumon can be increased when it is combined with Palbociclib.Approved
PhenytoinThe serum concentration of Palbociclib can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PilocarpineThe serum concentration of Pilocarpine can be increased when it is combined with Palbociclib.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Palbociclib.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Palbociclib.Approved
PinacidilThe serum concentration of Pinacidil can be increased when it is combined with Palbociclib.Withdrawn
PioglitazoneThe serum concentration of Pioglitazone can be increased when it is combined with Palbociclib.Approved, Investigational
PipotiazineThe serum concentration of Pipotiazine can be increased when it is combined with Palbociclib.Approved
PodofiloxThe serum concentration of Podofilox can be increased when it is combined with Palbociclib.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Palbociclib.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Palbociclib.Approved
PosaconazoleThe serum concentration of Palbociclib can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrasteroneThe serum concentration of Prasterone can be increased when it is combined with Palbociclib.Approved, Nutraceutical
PrasugrelThe serum concentration of Prasugrel can be increased when it is combined with Palbociclib.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Palbociclib.Approved
PrazepamThe serum concentration of Prazepam can be increased when it is combined with Palbociclib.Approved, Illicit
PraziquantelThe serum concentration of Praziquantel can be increased when it is combined with Palbociclib.Approved, Vet Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Palbociclib.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Palbociclib.Approved, Vet Approved
PrimaquineThe serum concentration of Primaquine can be increased when it is combined with Palbociclib.Approved
PrimidoneThe serum concentration of Palbociclib can be decreased when it is combined with Primidone.Approved, Vet Approved
ProchlorperazineThe serum concentration of Prochlorperazine can be increased when it is combined with Palbociclib.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Palbociclib.Approved, Vet Approved
ProguanilThe serum concentration of Proguanil can be increased when it is combined with Palbociclib.Approved
PromazineThe serum concentration of Promazine can be increased when it is combined with Palbociclib.Approved, Vet Approved
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Palbociclib.Approved
PropofolThe serum concentration of Propofol can be increased when it is combined with Palbociclib.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Palbociclib.Approved, Investigational
PyrazinamideThe serum concentration of Pyrazinamide can be increased when it is combined with Palbociclib.Approved
QuazepamThe serum concentration of Quazepam can be increased when it is combined with Palbociclib.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Palbociclib.Approved
QuinacrineThe serum concentration of Quinacrine can be increased when it is combined with Palbociclib.Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Palbociclib.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Palbociclib.Approved
RabeprazoleThe serum concentration of Rabeprazole can be increased when it is combined with Palbociclib.Approved, Investigational
Rabies vaccineThe risk or severity of adverse effects can be increased when Palbociclib is combined with Rabies vaccine.Approved
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Palbociclib.Approved
RaloxifeneThe serum concentration of Raloxifene can be increased when it is combined with Palbociclib.Approved, Investigational
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Palbociclib.Approved, Investigational
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Palbociclib.Approved, Investigational
ReboxetineThe serum concentration of Reboxetine can be increased when it is combined with Palbociclib.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Palbociclib.Approved
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Palbociclib.Approved, Investigational
RetapamulinThe serum concentration of Retapamulin can be increased when it is combined with Palbociclib.Approved
RifabutinThe serum concentration of Palbociclib can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Palbociclib can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Palbociclib can be decreased when it is combined with Rifapentine.Approved
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Palbociclib.Approved
RimonabantThe serum concentration of Rimonabant can be increased when it is combined with Palbociclib.Approved, Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Palbociclib.Approved
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Palbociclib.Approved, Investigational
RitonavirThe serum concentration of Palbociclib can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Palbociclib.Approved
RofecoxibThe serum concentration of Rofecoxib can be increased when it is combined with Palbociclib.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Palbociclib.Approved
RolapitantThe serum concentration of Rolapitant can be increased when it is combined with Palbociclib.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Palbociclib.Approved, Investigational
RopiniroleThe serum concentration of Ropinirole can be increased when it is combined with Palbociclib.Approved, Investigational
RopivacaineThe serum concentration of Ropivacaine can be increased when it is combined with Palbociclib.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Palbociclib.Approved
RotigotineThe serum concentration of Rotigotine can be increased when it is combined with Palbociclib.Approved
RoxithromycinThe serum concentration of Roxithromycin can be increased when it is combined with Palbociclib.Approved, Withdrawn
RuxolitinibThe serum concentration of Ruxolitinib can be increased when it is combined with Palbociclib.Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Palbociclib.Approved
SaquinavirThe serum concentration of Palbociclib can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Palbociclib.Approved
SelegilineThe serum concentration of Selegiline can be increased when it is combined with Palbociclib.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Palbociclib.Approved
SeratrodastThe serum concentration of Seratrodast can be increased when it is combined with Palbociclib.Approved, Investigational
SertindoleThe serum concentration of Sertindole can be increased when it is combined with Palbociclib.Approved, Withdrawn
SertralineThe serum concentration of Sertraline can be increased when it is combined with Palbociclib.Approved
SevofluraneThe serum concentration of Sevoflurane can be increased when it is combined with Palbociclib.Approved, Vet Approved
SibutramineThe serum concentration of Sibutramine can be increased when it is combined with Palbociclib.Approved, Illicit, Investigational, Withdrawn
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Palbociclib.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Palbociclib.Approved
SiltuximabThe serum concentration of Palbociclib can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Palbociclib.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Palbociclib.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Palbociclib.Approved
SirolimusThe serum concentration of Sirolimus can be increased when it is combined with Palbociclib.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Palbociclib.Approved, Investigational
SolifenacinThe serum concentration of Solifenacin can be increased when it is combined with Palbociclib.Approved
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Palbociclib.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Palbociclib.Approved, Investigational
SpiramycinThe serum concentration of Spiramycin can be increased when it is combined with Palbociclib.Approved
SRP 299The risk or severity of adverse effects can be increased when Palbociclib is combined with SRP 299.Investigational
St. John's WortThe serum concentration of Palbociclib can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Palbociclib can be increased when it is combined with Stiripentol.Approved
SufentanilThe serum concentration of Sufentanil can be increased when it is combined with Palbociclib.Approved, Investigational
SulfadiazineThe serum concentration of Sulfadiazine can be increased when it is combined with Palbociclib.Approved, Vet Approved
SulfamethoxazoleThe serum concentration of Sulfamethoxazole can be increased when it is combined with Palbociclib.Approved
SulfinpyrazoneThe serum concentration of Sulfinpyrazone can be increased when it is combined with Palbociclib.Approved
SulfisoxazoleThe metabolism of Palbociclib can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SunitinibThe serum concentration of Sunitinib can be increased when it is combined with Palbociclib.Approved, Investigational
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be increased when it is combined with Palbociclib.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Synthetic Conjugated Estrogens, B can be increased when it is combined with Palbociclib.Approved
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Palbociclib.Approved, Investigational
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Palbociclib.Approved, Investigational
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Palbociclib.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Palbociclib.Approved
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Palbociclib.Approved, Investigational
TasosartanThe serum concentration of Tasosartan can be increased when it is combined with Palbociclib.Approved
Taurochenodeoxycholic acidThe serum concentration of Taurochenodeoxycholic acid can be increased when it is combined with Palbociclib.Experimental
TelaprevirThe serum concentration of Palbociclib can be increased when it is combined with Telaprevir.Approved
TelithromycinThe serum concentration of Palbociclib can be increased when it is combined with Telithromycin.Approved
TemazepamThe serum concentration of Temazepam can be increased when it is combined with Palbociclib.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Palbociclib.Approved
TeniposideThe serum concentration of Teniposide can be increased when it is combined with Palbociclib.Approved
TerbinafineThe serum concentration of Terbinafine can be increased when it is combined with Palbociclib.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Palbociclib.Withdrawn
TesmilifeneThe serum concentration of Tesmilifene can be increased when it is combined with Palbociclib.Investigational
TestosteroneThe serum concentration of Testosterone can be increased when it is combined with Palbociclib.Approved, Investigational
TetracyclineThe serum concentration of Tetracycline can be increased when it is combined with Palbociclib.Approved, Vet Approved
TG4010The risk or severity of adverse effects can be increased when Palbociclib is combined with TG4010.Investigational
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Palbociclib.Approved
ThiotepaThe serum concentration of Thiotepa can be increased when it is combined with Palbociclib.Approved
TiagabineThe serum concentration of Tiagabine can be increased when it is combined with Palbociclib.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Palbociclib.Approved
TiclopidineThe serum concentration of Ticlopidine can be increased when it is combined with Palbociclib.Approved
TinidazoleThe serum concentration of Tinidazole can be increased when it is combined with Palbociclib.Approved, Investigational
TiotropiumThe serum concentration of Tiotropium can be increased when it is combined with Palbociclib.Approved
TipranavirThe serum concentration of Tipranavir can be increased when it is combined with Palbociclib.Approved, Investigational
TocilizumabThe serum concentration of Palbociclib can be decreased when it is combined with Tocilizumab.Approved
TofacitinibPalbociclib may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Palbociclib.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Palbociclib.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Palbociclib.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Palbociclib.Approved, Investigational
TramadolThe serum concentration of Tramadol can be increased when it is combined with Palbociclib.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Palbociclib.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Palbociclib.Approved
TrazodoneThe serum concentration of Trazodone can be increased when it is combined with Palbociclib.Approved, Investigational
TretinoinThe serum concentration of Tretinoin can be increased when it is combined with Palbociclib.Approved, Investigational, Nutraceutical
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Palbociclib.Approved, Vet Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Palbociclib.Approved
TrimethadioneThe serum concentration of Trimethadione can be increased when it is combined with Palbociclib.Approved
TrimethoprimThe serum concentration of Trimethoprim can be increased when it is combined with Palbociclib.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Palbociclib.Approved
TroglitazoneThe serum concentration of Troglitazone can be increased when it is combined with Palbociclib.Withdrawn
TroleandomycinThe serum concentration of Troleandomycin can be increased when it is combined with Palbociclib.Approved
UdenafilThe serum concentration of Udenafil can be increased when it is combined with Palbociclib.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Palbociclib.Approved
ValdecoxibThe serum concentration of Valdecoxib can be increased when it is combined with Palbociclib.Investigational, Withdrawn
VandetanibThe serum concentration of Vandetanib can be increased when it is combined with Palbociclib.Approved
VanoxerineThe serum concentration of Vanoxerine can be increased when it is combined with Palbociclib.Investigational
VardenafilThe serum concentration of Vardenafil can be increased when it is combined with Palbociclib.Approved
VemurafenibThe serum concentration of Vemurafenib can be increased when it is combined with Palbociclib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Palbociclib.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Palbociclib.Approved
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Palbociclib.Approved
VicrivirocThe serum concentration of Vicriviroc can be increased when it is combined with Palbociclib.Investigational
VilanterolThe serum concentration of Vilanterol can be increased when it is combined with Palbociclib.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Palbociclib.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Palbociclib.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Palbociclib.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Palbociclib.Approved
VinorelbineThe serum concentration of Vinorelbine can be increased when it is combined with Palbociclib.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Palbociclib.Approved
VoriconazoleThe serum concentration of Palbociclib can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Palbociclib.Approved
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Palbociclib.Approved
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Palbociclib.Approved, Vet Approved
ZafirlukastThe serum concentration of Zafirlukast can be increased when it is combined with Palbociclib.Approved, Investigational
ZalcitabineThe serum concentration of Zalcitabine can be increased when it is combined with Palbociclib.Approved
ZaleplonThe serum concentration of Zaleplon can be increased when it is combined with Palbociclib.Approved, Illicit, Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Palbociclib.Approved
ZileutonThe serum concentration of Zileuton can be increased when it is combined with Palbociclib.Approved, Investigational, Withdrawn
ZiprasidoneThe serum concentration of Ziprasidone can be increased when it is combined with Palbociclib.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Palbociclib.Approved
ZomepiracThe serum concentration of Zomepirac can be increased when it is combined with Palbociclib.Withdrawn
ZonisamideThe serum concentration of Zonisamide can be increased when it is combined with Palbociclib.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Palbociclib.Approved
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Dhillon S: Palbociclib: first global approval. Drugs. 2015 Apr;75(5):543-51. doi: 10.1007/s40265-015-0379-9. [PubMed:25792301 ]
  2. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL: Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3(11):1427-38. [PubMed:15542782 ]
  3. Logan JE, Mostofizadeh N, Desai AJ, VON Euw E, Conklin D, Konkankit V, Hamidi H, Eckardt M, Anderson L, Chen HW, Ginther C, Taschereau E, Bui PH, Christensen JG, Belldegrun AS, Slamon DJ, Kabbinavar FF: PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity. Anticancer Res. 2013 Aug;33(8):2997-3004. [PubMed:23898052 ]
  4. Authors unspecified: Palbociclib Extends Survival in Advanced Breast Cancer. Cancer Discov. 2015 Jul;5(7):OF5. doi: 10.1158/2159-8290.CD-NB2015-083. Epub 2015 Jun 2. [PubMed:26036642 ]
  5. Turner NC, Ro J, Andre F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K, Giorgetti C, Randolph S, Koehler M, Cristofanilli M: Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015 Jul 16;373(3):209-19. doi: 10.1056/NEJMoa1505270. Epub 2015 Jun 1. [PubMed:26030518 ]
  6. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Fowst C, Huang X, Kim ST, Randolph S, Slamon DJ: The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015 Jan;16(1):25-35. doi: 10.1016/S1470-2045(14)71159-3. Epub 2014 Dec 16. [PubMed:25524798 ]
  7. DeMichele A, Clark AS, Tan KS, Heitjan DF, Gramlich K, Gallagher M, Lal P, Feldman M, Zhang P, Colameco C, Lewis D, Langer M, Goodman N, Domchek S, Gogineni K, Rosen M, Fox K, O'Dwyer P: CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. Clin Cancer Res. 2015 Mar 1;21(5):995-1001. doi: 10.1158/1078-0432.CCR-14-2258. Epub 2014 Dec 11. [PubMed:25501126 ]
External Links
ATC CodesL01XE33
AHFS Codes
  • 10:00
PDB EntriesNot Available
FDA labelDownload (481 KB)
MSDSNot Available
ADMET
Predicted ADMET featuresNot Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
CapsuleOral100 mg/1
CapsuleOral100 mg
CapsuleOral125 mg/1
CapsuleOral125 mg
CapsuleOral75 mg/1
CapsuleOral75 mg
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6936612 No2003-01-222023-01-22Us
US7208489 No2003-01-162023-01-16Us
US7456168 No2003-01-162023-01-16Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
pKa7.4 (the secondary piperazine nitrogen) and 3.9 (the pyridine nitrogen)FDA Label
Predicted Properties
PropertyValueSource
Water Solubility0.0174 mg/mLALOGPS
logP2.12ALOGPS
logP2.77ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)11.34ChemAxon
pKa (Strongest Basic)8.86ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area103.35 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity127.47 m3·mol-1ChemAxon
Polarizability49.69 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as pyridinylpiperazines. These are compounds containing a pyridinylpiperazine skeleton, which consists of a pyridine linked (not fused) to a piperazine by a bond by a single bond that is not part of a ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazinanes
Sub ClassPiperazines
Direct ParentPyridinylpiperazines
Alternative Parents
Substituents
  • N-arylpiperazine
  • Pyridinylpiperazine
  • Pyridopyrimidine
  • Dialkylarylamine
  • Aryl alkyl ketone
  • Aryl ketone
  • Methylpyridine
  • Pyridinone
  • Aminopyridine
  • Imidolactam
  • Pyrimidine
  • Pyridine
  • Heteroaromatic compound
  • Vinylogous amide
  • Tertiary amine
  • Lactam
  • Ketone
  • Azacycle
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
Inhibitor
General Function:
Cyclin-dependent protein serine/threonine kinase regulator activity
Specific Function:
Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes that phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complexes and the subsequent transcription of E2F target genes which are responsible for the progres...
Gene Name:
CDK4
Uniprot ID:
P11802
Molecular Weight:
33729.55 Da
References
  1. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL: Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3(11):1427-38. [PubMed:15542782 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
Inhibitor
General Function:
Cyclin-dependent protein serine/threonine kinase activity
Specific Function:
Serine/threonine-protein kinase involved in the control of the cell cycle and differentiation; promotes G1/S transition. Phosphorylates pRB/RB1 and NPM1. Interacts with D-type G1 cyclins during interphase at G1 to form a pRB/RB1 kinase and controls the entrance into the cell cycle. Involved in initiation and maintenance of cell cycle exit during cell differentiation; prevents cell proliferation...
Gene Name:
CDK6
Uniprot ID:
Q00534
Molecular Weight:
36938.025 Da
References
  1. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL: Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3(11):1427-38. [PubMed:15542782 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
2. Sulfotransferase 2A1
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
Comments
comments powered by Disqus
Drug created on May 14, 2015 14:03 / Updated on December 07, 2016 02:40